Overview
The 46-Gene Signature (Prolaris) is a validated genomic test used for prognostic and predictive assessment in prostate cancer. As explained in the document (pages 2–6), Prolaris evaluates the expression of 46 genes, including 31 cell-cycle progression (CCP) genes and 15 housekeeping genes, to produce a Cell Cycle Progression (CCP) score. This score quantifies how quickly cancer cells are dividing and predicts the likelihood of disease progression, metastasis, and mortality.
The test is performed on existing biopsy or prostatectomy tissue, meaning patients do not need additional invasive procedures (page 2). It provides objective insight into tumor aggressiveness by integrating molecular analysis with traditional factors such as PSA levels, Gleason score, and tumor staging. Results help guide decisions regarding active surveillance, multimodal therapy, surgery, radiation, and long-term disease management (pages 4, 16).
For ER-positive breast cancer, the document (page 3) also notes the role of gene signatures—including ESR1 mutation assessment—in predicting recurrence and endocrine resistance. However, the core clinical application of the 46-gene Prolaris signature remains in localized prostate cancer, where it enhances risk stratification, treatment planning, and shared decision-making.
Symptoms
Prolaris is not a disease and therefore does not produce symptoms. Instead, it is used when patients show clinical features that raise suspicion for prostate cancer or when disease severity must be determined after diagnosis.
Symptoms That Lead to Testing
- Difficulty urinating or weak urine flow
- Pelvic discomfort or pressure
- Elevated PSA levels on routine screening
- Abnormal digital rectal examination
- Biopsy-confirmed prostate cancer requiring risk assessment
These symptoms prompt physicians to use Prolaris to determine whether the cancer is indolent or aggressive (pages 4, 8–9).
Symptoms Suggesting High-Risk or Progressive Disease
After diagnosis, symptoms such as:
- Bone pain
- Unintentional weight loss
- Worsening urinary symptoms
- Rising PSA after treatment
may warrant deeper evaluation using genomic scoring to predict metastasis or recurrence (pages 8–9, 16).
Causes
In this context, “causes” refer to biological mechanisms and clinical factors that make the 46-Gene Signature clinically necessary.
1. Tumor Cell Proliferation
The test targets genes controlling the cell cycle, including regulators of G1/S transition and mitosis (page 10). When these genes are overexpressed, cancer cells divide more rapidly, causing a more aggressive disease.
2. Molecular Changes Driving Aggressiveness
Expression shifts in proliferation markers and other cancer-associated genes contribute to faster tumor progression (page 10), influencing CCP scores.
3. Need for Accurate Prognosis Beyond Pathology
Traditional clinical tools cannot fully differentiate between indolent and high-risk disease. The document highlights that Prolaris offers stronger prognostic power than standard pathology (page 2).
4. Potential Endocrine Resistance in Other Cancer Types
The document notes that, in ER-positive breast cancer, ESR1 mutations lead to ligand-independent activity of the estrogen receptor, affecting recurrence (page 3). Gene signatures help predict treatment response.
5. Requirement for Personalized Therapy Planning
Treatment intensity must match tumor biology. Gene expression patterns reveal how the tumor behaves and estimate survival outcomes (pages 4, 15–17).
Risk Factors
Risk factors reflect the patient groups who benefit most from Prolaris testing.
1. Men With Localized Prostate Cancer
The strongest indication—used for risk stratification and guiding active surveillance vs. definitive treatment (page 4).
2. Patients With Medium to High Clinical Risk
Those with borderline PSA or ambiguous Gleason scores benefit from molecular clarification.
3. Post-Biopsy or Post-Prostatectomy Cases
Tissue collected during TUR, open prostatectomy, or biopsy is suitable for testing, including metastatic site tissue (page 13).
4. Individuals at Risk of Metastasis or Mortality
CCP score predicts metastatic progression and 10-year prostate cancer-specific mortality (page 16).
5. Patients Wanting Personalized Treatment Decisions
Prolaris helps avoid overtreatment in low-risk disease and supports early aggressive therapy for high-risk patients (pages 11, 16–17).
6. ER-Positive Breast Cancer Patients
For breast cancer, genomic signatures support endocrine therapy management and recurrence prediction (pages 3, 15).
Prevention
While Prolaris does not prevent cancer, it helps prevent inappropriate treatment and ensures precision-based management.
1. Use the Test Within Validated Groups
Interpretation is limited outside validated populations, as noted in the document (page 18).
2. Combine Genomic Scores With Other Clinical Parameters
The test is not stand-alone and must be correlated with imaging, PSA, tumor stage, and pathology (page 18).
3. Ensure Adequate Tissue Sampling
Requires proper paraffin-embedded blocks with sufficient tumor content (page 13), preventing inaccurate scoring.
4. Guide Treatment to Avoid Overtreatment
Genomic scoring helps reduce unnecessary surgeries and radiation—documented reductions include a 37.2% drop in interventions (page 11).
5. Support Early Detection of High-Risk Disease
The test enables early identification of aggressive tumors (page 17), improving long-term outcomes.
6. Follow Evidence-Based Guidelines
Prolaris is endorsed in clinical recommendations (page 17), ensuring prevention of clinical misjudgment by using validated genomic tools.
